Abstract
Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition
Keywords: Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.
Current Pharmaceutical Design
Title:Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches
Volume: 20 Issue: 32
Author(s): Hamendra Singh Parmar, Mahesh Kumar Bhinchar, Muskan Bhatia, Nikita Chordia, Ishan Raval, Digvijay Singh Chauhan, E. Manivannan, Rameshwar Jatwa and Anil Kumar
Affiliation:
Keywords: Alanine amino transaminase, alpha-amylase, aspartate aminotransferase, diabetes, dipeptidyl peptidase-IV, insulin, lipid peroxidation, urea.
Abstract: Glimepiride sulfonamide (GS) is a drug intermediate to synthesize glimepiride (antidiabetic drug). We hypothesized that GS exerts gluco-regulatory effect because GS is comprised of the structural components of dipeptidyl peptidase-IV (DPP-IV) inhibitors sitagliptin and DPP-728and glimepiride (sulfonylurea based antidiabetic drug).We analyzed the drug-likeness and docking efficiency of GS with DPP-IV using in silico tools. Also DPP-IV inhibition assays were conducted in vitro. Gluco-regulatory potential and parameters of drug safety were evaluated on normal euglycemic and streptozotocin (STZ) induced diabetic rats. We observed strong drug-likeness and DPP-IV binding efficiency of GS. Similarly, profound DPP-IV inhibition was also observed in vitro. Studies on euglycemic and STZ induced diabetic rats revealed antidiabetic potential for GS without significant change in the studied toxicological parameters. Glimepiride sulfonamide has antidiabetic potential mainly through DPP-IV inhibition, but also through insulin stimulation and alpha-amylase inhibition
Export Options
About this article
Cite this article as:
Parmar Singh Hamendra, Bhinchar Kumar Mahesh, Bhatia Muskan, Chordia Nikita, Raval Ishan, Chauhan Singh Digvijay, Manivannan E., Jatwa Rameshwar and Kumar Anil, Study on Gluco-Regulatory Potential of Glimepiride Sulfonamide Using In silico, In Vitro and In Vivo Approaches, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612820666140318114832
DOI https://dx.doi.org/10.2174/1381612820666140318114832 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer’s Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls
Current Alzheimer Research Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis
Current Drug Safety Seeds of Mung Bean (<i>Vigna radiata</i> (L.) R.Wilczek): Taxonomy, Phytochemistry, Medicinal Uses and Pharmacology
Current Bioactive Compounds Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Anti-Inflammatory Role of Fetuin-A in Injury and Infection
Current Molecular Medicine Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Control of Blood Pressure in the Community: An Unsolved Problem
Current Pharmaceutical Design Analysis of Contrast-Enhanced Intravascular Ultrasound Images for the Assessment of Coronary Plaque Neoangiogenesis: Another Step Closer to the Identification of the Vulnerable Plaque
Current Pharmaceutical Design Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design Renoprotective Effects of the L-/T-type Calcium Channel Blocker Benidipine in Patients with Hypertension
Current Hypertension Reviews Ticagrelor: A Novel Drug for an Old Problem
Recent Patents on Cardiovascular Drug Discovery Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics N-Aroylated Isatins: Antiglycation Activity
Letters in Drug Design & Discovery Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets